A Phase 3 interventional study of Nivolumab and Cabozantinib in Renal Cell Carcinoma, sponsored by Bristol-Myers Squibb. Completed at 135 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing nivolumab in Carcinoma, Renal Cell — 9 open to participants now, 23 under way, 3 of them phase 3. Nivolumab · Carcinoma, Renal Cell.
Among the 63 studies testing nivolumab in Carcinoma, Renal Cell, this one is the 9th largest by enrollment, is one of 13 that started in 2017, is one of 8 in phase 3, and was the 31st registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →9 of the 63 studies testing nivolumab in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Diwakar Davar · Sites in United States
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 70+
Mayo Clinic · Sites in United States
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in Austria, Czechia, France and 1 more country
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 39 · Phase 3 8 · Phase 4 4
First in 2006; this study’s year is marked. 13 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 701 is above the median of 43 across 1,565 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 54 across the 63 interventional studies. Of the 34 that completed or were terminated, 19 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 63 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb: 5 open now, 8 under way, 2 of them phase 3. Of 32 finished, 16 (50%) have results posted.
Among the 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb, this one is the 5th largest by enrollment of the 33 interventional ones that give a count, is one of 5 that started in 2017, is one of 6 in phase 3, and was the 23rd registered.
Bristol-Myers Squibb’s Carcinoma, Renal Cell studies by the year they started, since 2003.
9 of the studies testing nivolumab in Carcinoma, Renal Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04413123Bradley A. McGregor, MDCabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | 2026-12-20 |
| NCT02210117M.D. Anderson Cancer CenterNivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery | 2026-12-31 |
| NCT03866382National Cancer Institute (NCI)Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | 2027-02-28 |
| NCT04322955Mark SteinCYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition | 2027-05 |
| NCT06265285Mayo ClinicComparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | 2027-05-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 63 studies testing nivolumab in Carcinoma, Renal Cell, from their registry updates:
Among Bristol-Myers Squibb’s 42 in Carcinoma, Renal Cell:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
No prior systemic therapy for RCC with the following exception:
i) One prior or neoadjuvant therapy for completely resectable RCC if such therapy did not include an agent that targets VEGF or VEGF receptors and if recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nivolumab and Cabozantinib
Biological: Nivolumab · Drug: Cabozantinib
Sunitinib
Drug: Sunitinib
Nivolumab, Ipilimumab, Cabozantinib \*Enrollment to the triplet arm was discontinued by protocol amendment
Biological: Ipilimumab
Specified dose on specified day
Also known as: Opdivo, BMS-936558
Specified dose on specified days
Also known as: Cabometyx
Specified dose on specified days.
Also known as: Sutent
Specified dose on specified days
Also known as: Yervoy, BMS-734016
Progression Free Survival (PFS)
PFS is defined as the time from date of randomization to the first documented tumor progression date or death due to any cause, whichever occurs first based on BICR assessment using RECIST v1.1. Participants who die without a reported progression will be considered to have progressed on the date of their death. Participants who did not progress or die will be censored on the date of their last evaluable tumor assessment on or prior to initiation of subsequent anti-cancer therapy. Progressive disease (PD); 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study
Time frame: From randomization date to date of first documented tumor progression or death, whichever occurs first (Up to 31 months)
Overall Survival (OS)
Overall Survival is defined as the time between the date of randomization and the date of death due to any cause. For participants that are alive, their survival time will be censored at the date of last contact date (or "last known alive date").
Time frame: From randomization date to death date (Up to 31 months)
Objective Response Rate (ORR)
Objective Response Rate (ORR) is defined as the percentage of randomized participants who achieve a best response of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1 criteria) divided by the number of all randomized participants. Complete response (CR): Disappearance of all target lesions. Partial response (PR): 30% decrease in the sum of diameters of target lesions.
Time frame: Up to 31 Months
Number of Participants Experiencing Adverse Events (AEs)
Number of participants experiencing various types of any grade adverse events (AEs) during the specified time frame.
Time frame: From first dose to 100 days following last dose (Up to 32 Months)
Number of Participants Experiencing Serious Adverse Events (SAEs)
Number of participants experiencing various types of any grade serious adverse events (SAEs) during the specified time frame.
Time frame: From first to dose to 100 days following last dose (Up to 32 months)
Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
Number of participants experiencing various types of any grade adverse events (AEs) leading to discontinuation during the specified time frame.
Time frame: From first dose to 30 days following last dose (Up to 30 months)
Number of Deaths
Number of deaths due to any cause during the specified time frame.
Time frame: From first dose to (up to 31 months) following first dose
Number of Participants With Laboratory Abnormalities
Number of participants experiencing laboratory abnormalities in hematology, serum chemistry and electrolytes with grade 3 or higher during the specified time frame.
Time frame: From first dose to 30 days following last dose (Up to 30 Months)
Number of Participants With Laboratory Values Grade Shifting From Baseline
Number of participants experiencing worsening shift from baseline in any grade and grade 3-4 of laboratory values during the specified time frame.
Time frame: From first dose to 30 days following last dose (Up to 30 Months)
| Milestone | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Started | 323 | 50 | 328 |
| Treated | 320 | 50 | 320 |
| Completed | 242 | 34 | 210 |
| Not completed | 81 | 16 | 118 |
| Withdrew: Death | 62 | 13 | 84 |
| Withdrew: Participant withdrew consent | 9 | 2 | 13 |
| Withdrew: Not reported | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 1 | 1 |
| Withdrew: Other reasons | 4 | 0 | 11 |
| Withdrew: Participants did not start treatment period | 3 | 0 | 8 |
PFS is defined as the time from date of randomization to the first documented tumor progression date or death due to any cause, whichever occurs first based on BICR assessment using RECIST v1.1. Participants who die without a reported progression will be considered to have progressed on the date of their death. Participants who did not progress or die will be censored on the date of their last evaluable tumor assessment on or prior to initiation of subsequent anti-cancer therapy. Progressive disease (PD); 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study
| Months | Treatment A | Treatment C |
|---|---|---|
| Progression Free Survival (PFS) | 16.59 (12.45 to 24.94) | 8.31 (6.97 to 9.69) |
Overall Survival is defined as the time between the date of randomization and the date of death due to any cause. For participants that are alive, their survival time will be censored at the date of last contact date (or "last known alive date").
| Months | Treatment A | Treatment C |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (22.6 to NA) |
Objective Response Rate (ORR) is defined as the percentage of randomized participants who achieve a best response of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1 criteria) divided by the number of all randomized participants. Complete response (CR): Disappearance of all target lesions. Partial response (PR): 30% decrease in the sum of diameters of target lesions.
| Percentage of Participants | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Objective Response Rate (ORR) | 55.7 (50.1 to 61.2) | 44.0 (30.0 to 58.7) | 27.1 (22.4 to 32.3) |
Number of participants experiencing various types of any grade adverse events (AEs) during the specified time frame.
| Participants | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Number of Participants Experiencing Adverse Events (AEs) | 319 | 50 | 317 |
Number of participants experiencing various types of any grade serious adverse events (SAEs) during the specified time frame.
| Participants | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Number of Participants Experiencing Serious Adverse Events (SAEs) | 160 | 28 | 144 |
Number of participants experiencing various types of any grade adverse events (AEs) leading to discontinuation during the specified time frame.
| Participants | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 63 | 15 | 54 |
Number of deaths due to any cause during the specified time frame.
| Participants | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Number of Deaths | 67 | 14 | 99 |
Number of participants experiencing laboratory abnormalities in hematology, serum chemistry and electrolytes with grade 3 or higher during the specified time frame.
| Participants | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Hemoglobin: Any grade | 235 | 35 | 256 |
| Hemoglobin: Grade 3-4 | 9 | 5 | 15 |
| Platelet Count: Any grade | 137 | 27 | 216 |
| Platelet Count: Grade 3-4 | 1 | 0 | 30 |
| Leukocytes: Any grade | 121 | 26 | 207 |
| Leukocytes: Grade 3-4 | 1 | 0 | 16 |
| Lymphocytes: Any grade | 107 | 22 | 118 |
| Lymphocytes: Grade 3-4 | 16 | 4 | 24 |
| Neutrophil: Any grade | 115 | 22 | 209 |
| Neutrophil: Grade 3-4 | 10 | 2 | 36 |
| Alkaline Phosphatase: Any grade | 194 | 35 | 167 |
| Alkaline Phosphatase: Grade 3-4 | 12 | 6 | 6 |
| Aspartate Aminotransferase (AST): Any grade | 260 | 43 | 235 |
| Aspartate Aminotransferase (AST): Grade 3-4 | 25 | 19 | 8 |
| Alanine Aminotransferase (ALT): Any grade | 268 | 46 | 133 |
| Alanine Aminotransferase (ALT): Grade 3-4 | 31 | 24 | 11 |
| Bilirubin: Any grade | 57 | 17 | 72 |
| Bilirubin: Grade 3-4 | 3 | 3 | 3 |
| Creatinine: Any grade | 221 | 34 | 211 |
| Creatinine: Grade 3-4 | 4 | 0 | 2 |
| Amylase: Any grade | 48 | 28 | 41 |
| Amylase: Grade 3-4 | 30 | 10 | 17 |
| Lipase: Any grade | 36 | 27 | 42 |
| Lipase: Grade 3-4 | 46 | 20 | 41 |
| Hypernatremia: Any grade | 33 | 7 | 24 |
| Hypernatremia: Grade 3-4 | 0 | 0 | 0 |
| Hyponatremia: Any grade | 160 | 31 | 140 |
| Hyponatremia: Grade 3-4 | 36 | 9 | 41 |
| Hyperkalemia: Any grade | 136 | 27 | 100 |
| Hyperkalemia: Grade 3-4 | 16 | 2 | 3 |
| Hypokalemia: Any grade | 64 | 8 | 37 |
| Hypokalemia: Grade 3-4 | 11 | 0 | 6 |
| Hypercalcemia: Any grade | 40 | 9 | 58 |
| Hypercalcemia: Grade 3-4 | 1 | 0 | 4 |
| Hypocalcemia: Any grade | 174 | 25 | 77 |
| Hypocalcemia: Grade 3-4 | 6 | 2 | 2 |
| Hypermagnesemia: Any grade | 42 | 9 | 29 |
| Hypermagnesemia: Grade 3-4 | 12 | 4 | 7 |
| Hypomagnesemia: Any grade | 155 | 18 | 90 |
| Hypomagnesemia: Grade 3-4 | 4 | 1 | 1 |
| Hyperphosphatemia: Any grade | 0 | 0 | 0 |
| Hyperphosphatemia: Grade 3-4 | 0 | 0 | 0 |
| Hypophosphatemia: Any grade | 226 | 34 | 154 |
| Hypophosphatemia: Grade 3-4 | 88 | 12 | 31 |
| Hyperglycemia: Any grade | 135 | 29 | 139 |
| Hyperglycemia: Grade 3-4 | 8 | 2 | 4 |
| Hypoglycemia: Any grade | 72 | 10 | 41 |
| Hypoglycemia: Grade 3-4 | 2 | 1 | 1 |
Number of participants experiencing worsening shift from baseline in any grade and grade 3-4 of laboratory values during the specified time frame.
| Participants | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Hemoglobin: Any grade | 117 | 23 | 190 |
| Hemoglobin: Grade 3-4 | 8 | 5 | 15 |
| Platelet Count: Any grade | 129 | 24 | 216 |
| Platelet Count: Grade 3-4 | 2 | 0 | 30 |
| Leukocytes: Any grade | 116 | 26 | 206 |
| Leukocytes: Grade 3-4 | 1 | 0 | 16 |
| Lymphocytes: Any grade | 95 | 20 | 102 |
| Lymphocytes: Grade 3-4 | 15 | 4 | 23 |
| Neutrophil: Any grade | 112 | 22 | 209 |
| Neutrophil: Grade 3-4 | 10 | 2 | 36 |
| Alkaline Phosphatase: Any grade | 131 | 31 | 115 |
| Alkaline Phosphatase: Grade 3-4 | 9 | 6 | 5 |
| Aspartate Aminotransferase (AST): Any grade | 245 | 42 | 177 |
| Aspartate Aminotransferase (AST): Grade 3-4 | 25 | 19 | 8 |
| Alanine Aminotransferase (ALT): Any grade | 249 | 43 | 121 |
| Alanine Aminotransferase (ALT) Grade 3-4 | 31 | 24 | 11 |
| Bilirubin: Any grade | 55 | 17 | 68 |
| Bilirubin: Grade 3-4 | 3 | 3 | 3 |
| Creatinine: Any grade | 123 | 22 | 132 |
| Creatinine: Grade 3-4 | 4 | 0 | 2 |
| Amylase: Any grade | 117 | 26 | 77 |
| Amylase: Grade 3-4 | 28 | 10 | 16 |
| Lipase: Any grade | 127 | 27 | 114 |
| Lipase: Grade 3-4 | 42 | 20 | 40 |
| Hypernatremia: Any grade | 33 | 7 | 24 |
| Hypernatremia: Grade 3-4 | 0 | 0 | 0 |
| Hyponatremia: Any grade | 136 | 30 | 111 |
| Hyponatremia: Grade 3-4 | 34 | 8 | 37 |
| Hyperkalemia: Any grade | 111 | 25 | 82 |
| Hyperkalemia: Grade 3-4 | 15 | 2 | 3 |
| Hypokalemia: Any grade | 61 | 8 | 35 |
| Hypokalemia: Grade 3-4 | 10 | 0 | 5 |
| Hypercalcemia: Any grade | 30 | 7 | 46 |
| Hypercalcemia: Grade 3-4 | 1 | 0 | 3 |
| Hypocalcemia: Any grade | 170 | 25 | 73 |
| Hypocalcemia: Grade 3-4 | 6 | 2 | 2 |
| Hypermagnesemia: Any grade | 38 | 9 | 26 |
| Hypermagnesemia: Grade 3-4 | 12 | 4 | 7 |
| Hypomagnesemia: Any grade | 146 | 16 | 77 |
| Hypomagnesemia: Grade 3-4 | 4 | 1 | 1 |
| Hyperphosphatemia: Any grade | 0 | 0 | 0 |
| Hyperphosphatemia: Grade 3-4 | 0 | 0 | 0 |
| Hypophosphatemia: Any grade | 211 | 33 | 147 |
| Hypophosphatemia: Grade 3-4 | 85 | 12 | 31 |
| Hyperglycemia: Any grade | 74 | 17 | 76 |
| Hyperglycemia: Grade 3-4 | 6 | 2 | 3 |
| Hypoglycemia: Any grade | 67 | 9 | 37 |
| Hypoglycemia: Grade 3-4 | 2 | 1 | 1 |
Collected over All cause mortality: From first visit to up to 31 months following first visit SAEs and AEs: From first dose to 100 days following last dose (up to 32 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | 67/320 (20.9%) | 160/320 (50%) | 316/320 (98.8%) |
| Treatment B | 14/50 (28%) | 28/50 (56%) | 48/50 (96%) |
| Treatment C | 99/320 (30.9%) | 144/320 (45%) | 306/320 (95.6%) |
| Event | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| PneumoniaInfections and infestations | 9/320 | 4/50 | 8/320 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 24/320 | 4/50 | 23/320 |
| DiarrhoeaGastrointestinal disorders | 15/320 | 0/50 | 0/320 |
| Adrenal insufficiencyEndocrine disorders | 6/320 | 2/50 | 0/320 |
| HepatitisHepatobiliary disorders | 2/320 | 2/50 | 0/320 |
| SyncopeNervous system disorders | 2/320 | 2/50 | 1/320 |
| AnaemiaBlood and lymphatic system disorders | 2/320 | 1/50 | 11/320 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/320 | 0/50 | 9/320 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 9/320 | 0/50 | 1/320 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 9/320 | 0/50 | 3/320 |
| Event | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 202/320 | 28/50 | 151/320 |
| Alanine aminotransferase increasedInvestigations | 90/320 | 21/50 | 28/320 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 128/320 | 20/50 | 130/320 |
| FatigueGeneral disorders | 102/320 | 19/50 | 112/320 |
| HypertensionVascular disorders | 112/320 | 18/50 | 121/320 |
| HypothyroidismEndocrine disorders | 109/320 | 15/50 | 95/320 |
| Aspartate aminotransferase increasedInvestigations | 82/320 | 16/50 | 36/320 |
| NauseaGastrointestinal disorders | 86/320 | 15/50 | 99/320 |
| Decreased appetiteMetabolism and nutrition disorders | 92/320 | 15/50 | 66/320 |
| RashSkin and subcutaneous tissue disorders | 69/320 | 15/50 | 26/320 |
| Age, Continuous(Years) | Treatment A | Treatment B | Treatment C | Total |
|---|---|---|---|---|
| Mean | 61.4 ± 10.2 | 60.3 ± 9.5 | 60.4 ± 10.6 | 60.9 ± 10.4 |
| Sex: Female, Male(Participants) | Treatment A | Treatment B | Treatment C | Total |
|---|---|---|---|---|
| Female | 74 | 16 | 96 | 186 |
| Male | 249 | 34 | 232 | 515 |
| Ethnicity (NIH/OMB)(Participants) | Treatment A | Treatment B | Treatment C | Total |
|---|---|---|---|---|
| Hispanic or Latino | 38 | 13 | 39 | 90 |
| Not Hispanic or Latino | 149 | 19 | 151 | 319 |
| Unknown or Not Reported | 136 | 18 | 138 | 292 |
| Race (NIH/OMB)(Participants) | Treatment A | Treatment B | Treatment C | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 3 | 0 | 2 | 5 |
| Asian | 26 | 0 | 25 | 51 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 4 | 5 |
| White | 267 | 43 | 266 | 576 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 26 | 7 | 31 | 64 |
Showing the first 100 of 135 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2017 to primary completion in Feb 2020, 30 months.
Results were first posted in Apr 2022, 2 years 2 months after primary completion. A results delay was requested in Feb 2021.
Of 35 industry-sponsored phase 3 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 59. This study's 30 months is below that.
Counting every sponsor, half of 61 studies reached it within 56 months; a quarter within 42 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Cabozantinib · Ipilimumab